Clinical Trials Logo

Immunodeficiency With Hyper-IgM clinical trials

View clinical trials related to Immunodeficiency With Hyper-IgM.

Filter by:
  • None
  • Page 1

NCT ID: NCT00278954 Completed - Clinical trials for Primary Immunodeficiency

Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.

Start date: January 2006
Phase: Phase 3
Study type: Interventional

The main objective of this study is to see if GAMMAPLEX is efficacious with respect to Food and Drug Administration (FDA) minimal requirements (no more than 1 serious, acute, bacterial infection per subject per year) in subjects with Primary Immunodeficiency Diseases (PID). The secondary objectives are to assess the safety and tolerability of GAMMAPLEX and to determine if GAMMAPLEX has a pharmacokinetic (PK) profile comparable with that of intact Immunoglobulin G (IgG) in subjects with PID.